Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2009 - 2026)

Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) history runs 18 years deep, the most recent figure standing at $4.02 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) rose 61.45% year-over-year to $4.02; the TTM figure through Mar 2026 stood at $16.85 (up 533.16% YoY), while the FY2025 annual figure was $15.32, up 836.54% from the prior year.
• EPS (Weighted Average and Diluted) was $4.02 for Q1 2026 at Vertex Pharmaceuticals, down from $4.64 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.64 in Q4 2025 to a low of -$13.92 in Q2 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged $2.58 across 5 years, with a median of $3.59 in 2022.
• The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) surged 1103.85% in 2022, then plunged 495.45% in 2024.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.14 in 2022, then gained by 18.15% to $3.71 in 2023, then decreased by 4.85% to $3.53 in 2024, then soared by 31.44% to $4.64 in 2025, then slipped by 13.36% to $4.02 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $4.02 (Q1 2026), $4.64 (Q4 2025), and $4.2 (Q3 2025), per Business Quant data.